Shots:

• The P-III trial involves assessing REGN-COV2 with an expected enrollment of 2000 patients at 100 sites which will be evaluated to prevent infection among uninfected people who have had close exposure to a COVID-19 patient
• REGN-COV2 is also being evaluated in P-II/III portion of two P-I/II/III trials testing the cocktail's ability to treat hospitalized (N= 1-850) and non-hospitalized (N=1050) patients with COVID-19 across 150 sites in the US- Brazil- Mexico- and Chile with expected results in late summer. Additionally- clinical progress follows positive recommendations from IDMC of P-I trial which involved assessing of REGN-COV2 in 30 hospitalized and non-hospitalized patients with COVID-19   
• REGN-COV2 is double-antibody cocktail developed using VelociMab and manufacturing capabilities for the prevention and treatment of COVID-19

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance